The debate revealed fundamental uncertainty about whether enhancing TYROBP-SYK signaling would be beneficial or harmful, with existing drugs being SYK inhibitors. This mechanistic gap is critical for determining if downstream TREM2 pathway activation is a viable therapeutic strategy. Source: Debate session sess_sda-2026-04-01-001 (Analysis: sda-2026-04-01-001)
Landscape Summary: Does SYK activation provide neuroprotection or exacerbate neuroinflammation in established Alzheimer's disease? is a 0.9 priority gap in neurodegeneration. It has 0 linked hypotheses with average composite score 0.000. Status: partially_addressed.
Colonna, Sevlever, et al. (TREM2 biology)
Does SYK activation provide neuroprotection or exacerbate neuroinflammation in established Alzheimer's disease? — INVOKE-2 (completed)
No hypotheses linked to this gap yet.
No discussions yet. Be the first to comment.
Create sub-tasks to investigate specific aspects of this gap: